uniQure Announces Additional Data from Ongoing Phase I/II Studies of ifezuntirgene inilparvovec (AMT-130) in Huntington’s Disease Showing Continued Slowing of Disease Progression
~ In 12 high-dose patients at 48 months, both cUHDRS and TFC continued to demonstrate meaningful slowing of disease progression and clear dose-dependent response; the primary endpoint of cUHDRS showed 44% slowing of disease progression (non-significant p=0.144) and TFC showed a 61% slowing of disease progression (nominal p=0.008) ~
Covered in this story
What has happened since
- American Tower is up 9.7% since this was published, 21 days ago.
- Truist Financial is up 1.9% since this was published, 21 days ago.
Price move measured from the close nearest publication to the latest quote.
Call it yourself
No calls on $AMT yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on American Tower →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.